Biblio Discovery — Demo Discovery Service

6 results for "Li-jun Chen"

Showing 1–6 · 0.64 seconds · RSS

  1. Journal Article Full text

    Activation of farnesoid X receptor upregulates binding immunoglobulin protein expression and alleviates diabetic nephropathy

    Tang, Jian-Ying; Chong, Yuan-Jia; Yang, Lu et al.

    World J Diabetes · 2025 · English · PubMed Central

    BACKGROUND: The exact mechanisms underlying diabetic nephropathy (DN) remain incompletely elucidated, prompting researchers to explore new perspectives and identify novel intervention targets in this field. AIM: To explore the role and underlying mechanisms of farnesoid X receptor (FXR) in the…

  2. Journal Article Full text

    Efficacy and safety of Runzao Zhiyang capsule for chronic urticaria: a systematic review and meta-analysis of randomized controlled trials

    Zhang, Jian-Feng; Wang, Ying-Dong; Lin, Peng et al.

    Front Pharmacol · 2023 · English · PubMed Central

    Background: Chronic urticaria (CU) is a commonly seen skin disorder featured by recurring wheals, with or without angioedema, lasting for at least 6 weeks. Runzao Zhiyang capsule (RZC) has been widely applied to treat patients with CU. This study is aimed at systematically evaluating the efficacy…

  3. Journal Article Full text

    The Partial Role of KLF4 and KLF5 in Gastrointestinal Tumors

    Li, Jun-Chen; Chen, Qiu-Han; Jian, Rui et al.

    Gastroenterol Res Pract · 2021 · English · PubMed Central

    BACKGROUND: KLF4 and KLF5 are members of the KLF transcription factor family, which play an important role in many gastrointestinal tumors. To gain a deeper insight into its function and role, bioinformatics was used to analyze the function and role of KLF4 and KLF5 in gastrointestinal tumors…

  4. Journal Article Full text

    PD‐1/PD‐L1 inhibitors‐based treatment for advanced renal cell carcinoma: Mechanisms affecting efficacy and combination therapies

    Ding, Lei; Dong, Hui yu; Zhou, Tian ren et al.

    Cancer Med · 2021 · English · PubMed Central

    With the widespread use of PD‐1/PD‐L1 monoclonal antibodies (mAbs) in the treatment of multiple malignant tumors, they were also gradually applied to advanced renal cell carcinoma (aRCC). Nowadays, multiple PD‐1/PD‐L1 mAbs, such as nivolumab, avelumab, and pembrolizumab, have achieved considerable…